Scientists unveil first molecular-level analysis of Omicron spike protein
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
List view / Grid view
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
Japanese researchers have formed ordered biological structures using protein needles, enabling protein self-assembly into lattice structures.
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
Urea cycle disorders affect the liver’s ability to excrete urea from the body. To test potential therapeutics requires an accurate model – a hurdle that has now been successfully navigated thanks to a team of researchers in Switzerland.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
A new potential mRNA vaccine that delivers instructions for making two key HIV proteins has been tested in mice and rhesus macaques.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.
Taking a novel approach to antibiotic discovery, researchers at Rockefeller University have hit upon a promising solution to the problem of superbugs – a pervasive threat in hospitals the world over.
The capability to edit genes has been transformative in opening therapeutic avenues for hitherto untreatable diseases and aiding biological insight. Scientists have now discovered a way to enhance this process using retrons, making the process more efficient and effective.
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
Read about the latest addition Invitrogen™ TrueCut™ HiFi Cas9 Protein to support your application and research goals.